- Home
- ADXN vs RDHL Comparison
ADXN vs RDHL Comparison
Compare ADXN & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADXN | RDHL |
|---|---|---|
| Founded | 2002 | 2009 |
| Country | Switzerland | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6M | 3.3M |
| IPO Year | 2019 | 2012 |
Fundamental Metrics
Financial Performance| Metric | ADXN | RDHL |
|---|---|---|
| Price | $3.53 | $0.55 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 39.3K | ★ 2.6M |
| Earning Date | 04-30-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $86.57 | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.10 | $0.54 |
| 52 Week High | $11.97 | $2.79 |
Technical Indicators
Market Signals| Indicator | ADXN | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 35.44 | 38.72 |
| Support Level | N/A | N/A |
| Resistance Level | $7.37 | $0.76 |
| Average True Range (ATR) | 0.28 | 0.06 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 40.74 | 2.07 |
Price Performance
Historical ComparisonAbout ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About RDHL Redhill Biopharma Ltd.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.